Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study

BACKGROUND: Pirfenidone is an anti-fibrotic agent shown to slow the progression of idiopathic pulmonary fibrosis (IPF). However, its effectiveness in association with serological autoimmune features in IPF remains unclear. METHODS: We retrospectively reviewed the medical records of patients with IPF...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Pulm Med
Auteurs principaux: Song, Myung Jin, Lee, Sang Hoon, Jung, Ji Ye, Kang, Young Ae, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kim, Song Yee
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8091553/
https://ncbi.nlm.nih.gov/pubmed/33941141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-021-01516-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires